Biotechnology argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART® (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual Meeting April 5, 2022
Biotechnology Strength Seen in Galapagos NV (GLPG): Can Its 5% Jump Turn into More Strength? April 4, 2022
Biotechnology Strength Seen in Cue Biopharma, Inc. (CUE): Can Its 6.4% Jump Turn into More Strength? April 4, 2022
Biotechnology Apellis Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference April 4, 2022
Biotechnology BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) April 3, 2022
Search
Biotechnology
